AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Curability beliefs regarding cancer prognosis
Number of subjects: 206
Study 32739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic understanding and its association with HIPs
Number of subjects: 206
Study 32739562 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic understanding and its association with religiosity and quality of life
Number of subjects: 206
Study 34547529 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 16 weeks (2Q16)
Number of subjects: 0
Study 34547529 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg aflibercept every 8 weeks as needed (2Q8PRN)
Number of subjects: 0
Study 34547529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections
Number of subjects: 0
Study 33235104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 16
Study 33235104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 16
Study 33235104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 16
Study 33235104 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 16
Study 33235104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 34534493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS) 12.5 grams intravenously
Number of subjects: 380
Study 34534493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 34534493 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium thiosulfate (STS)
Number of subjects: 380
Study 32434978 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-fiber-reinforced resin composite (SFRC)
Number of subjects: 76
Study 32434978 — intervention group
Group type: COMPARATOR
Intervention: Chairside indirect restorations (Grandioso inlay system)
Number of subjects: 76
Study 33181046 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIGN intervention (Assessing & Listening to Individual Goals and Needs)
Number of subjects: 120
Study 33181046 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 33181046 — intervention group
Group type: EXPERIMENTAL
Intervention: ALIGN intervention
Number of subjects: 120
Study 33510892 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg Curcuma longa
Number of subjects: 78
Study 33510892 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg Curcuma longa
Number of subjects: 78
Study 33510892 — intervention group
Group type: COMPARATOR
Intervention: Simethicone
Number of subjects: 78
Study 34008052 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily inhaled budesonide
Number of subjects: 80
Study 34008052 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily inhaled budesonide
Number of subjects: 80
Study 34753452 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (Cape) + Oxaliplatin (Oxa)
Number of subjects: 4307
Study 34753452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU) + Oxaliplatin (Oxa)
Number of subjects: 4307
Study 34753452 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4307
Study 34753452 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole
Number of subjects: 4307
Study 32448136 — intervention group
Group type: EXPERIMENTAL
Intervention: CareDose 4D low-dose CT combined with Karl 3D technology
Number of subjects: 60
Study 32448136 — intervention group
Group type: COMPARATOR
Intervention: Regular CT (control group)
Number of subjects: 60
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate therapy (40-75 mg/kg)
Number of subjects: 816
Study 34279646 — intervention group
Group type: COMPARATOR
Intervention: 5.5% saline placebo
Number of subjects: 816
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (2011-2016)
Number of subjects: 816
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy (2017-2019)
Number of subjects: 816
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional albuterol use
Number of subjects: 816
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in PRAM score at disposition (per 1-U increase)
Number of subjects: 816
Study 34279646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium therapy in children with a disposition PRAM score of 3 or lower
Number of subjects: 816
Study 32189664 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 HBOTs at 150 kPa/60 minutes, once daily, 5 days per week for 8 weeks
Number of subjects: 63
Study 32189664 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 63
Study 35419791 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery focused pelvic floor exercise (MOPEXE)
Number of subjects: 85
Study 35419791 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized purified flavanoid fraction (MPFF)
Number of subjects: 85
Study 35419791 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 85
Study 35419791 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NS)
Number of subjects: 85
Study 35419791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 85
Study 33779016 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of tobacco advertising banners
Number of subjects: 1099
Study 33779016 — intervention group
Group type: COMPARATOR
Intervention: Proximity to schools
Number of subjects: 1099
Study 33779016 — intervention group
Group type: COMPARATOR
Intervention: Other exposure measures (physical decay, presence of mosques, churches)
Number of subjects: 1099
Study 35404135 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomosis
Number of subjects: 90
Study 35404135 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomosis
Number of subjects: 90
Study 34294923 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNB1618 (engineered E. coli Nissle 1917)
Number of subjects: 14
Study 34294923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 32109425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 32109425 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 7.5 mg
Number of subjects: 253
Study 32109425 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 20 mg
Number of subjects: 253
Study 32109425 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Number of subjects: 253
Study 35679950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan triple therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Number of subjects: 1046
Study 35679950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan dual therapy (20 mg vonoprazan twice daily; 1 g amoxicillin 3 times daily)
Number of subjects: 1046
Study 35679950 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole triple therapy (30 mg lansoprazole; 1 g amoxicillin; 500 mg clarithromycin)
Number of subjects: 1046
Study 35679950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan triple therapy
Number of subjects: 1046
Study 35679950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan dual therapy
Number of subjects: 1046
Study 35679950 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole triple therapy
Number of subjects: 1046
Study 35750038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy
Number of subjects: 36
Study 35750038 — intervention group
Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and anthracycline-based chemotherapy
Number of subjects: 36
Study 35750038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Number of subjects: 36
Study 35750038 — intervention group
Group type: COMPARATOR
Intervention: Placebo with nab-paclitaxel and anthracycline-based chemotherapy (PD-L1-positive population)
Number of subjects: 36
Study 35750038 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 840 mg every 2 weeks
Number of subjects: 36
Study 35750038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 32436733 — intervention group
Group type: EXPERIMENTAL
Intervention: Etonogestrel implant
Number of subjects: 140
Study 32436733 — intervention group
Group type: COMPARATOR
Intervention: Short-acting reversible contraception (SARC)
Number of subjects: 140
Study 32436733 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal contraception
Number of subjects: 140
Study 35729713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozoralizumab plus MTX
Number of subjects: 381
Study 33825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for intermediate risk patients (score 5-8)
Number of subjects: 1053
Study 33825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for high risk patients (score >8)
Number of subjects: 1053
Study 33825274 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-fungal prophylaxis for low risk patients (score 0-4)
Number of subjects: 1053
Study 32977404 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (160 mg/day)
Number of subjects: 0
Study 32977404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2000 mg DHA + 400 mg EPA/day)
Number of subjects: 0
Study 32977404 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of curcumin and fish oil
Number of subjects: 0
Study 32977404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36445151 — intervention group
Group type: EXPERIMENTAL
Intervention: TECAS (Transcutaneous electrical cranial-auricular acupoint stimulation)
Number of subjects: 468
Study 36445151 — intervention group
Group type: COMPARATOR
Intervention: escitalopram
Number of subjects: 468
Study 33473019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (NSAID)
Number of subjects: 94
Study 33473019 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID and antihistaminic drug combination
Number of subjects: 94
Study 33473019 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo drug
Number of subjects: 94
Study 33473019 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracanal cryotherapy
Number of subjects: 94
Study 33473019 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 94
Study 32609523 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive Vibration Exercise (RVE)
Number of subjects: 8
Study 32609523 — intervention group
Group type: EXPERIMENTAL
Intervention: NEX (RVE combined with whey protein supplementation and alkaline salt)
Number of subjects: 8
Study 32609523 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 8
Study 34932885 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+EX
Number of subjects: 0
Study 34932885 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+SL
Number of subjects: 0
Study 34932885 — intervention group
Group type: EXPERIMENTAL
Intervention: WL+EX+SL
Number of subjects: 0
Study 34173923 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 37
Study 34173923 — intervention group
Group type: COMPARATOR
Intervention: i-view™ video laryngoscope
Number of subjects: 37
Study 34173923 — intervention group
Group type: COMPARATOR
Intervention: C-MAC® video laryngoscope
Number of subjects: 37
Study 93178847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy for 26 weeks
Number of subjects: 53
Study 93178847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa therapy
Number of subjects: 53
Study 35968668 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainers (VFR) in the mandible (n=52)
Number of subjects: 104
Study 35968668 — intervention group
Group type: COMPARATOR
Intervention: Bonded cuspid-to-cuspid retainers (CTC) (n=52)
Number of subjects: 104
Study 35968668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups had a VFR in the maxilla
Number of subjects: 104
Study 35968668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VFR and CTC)
Number of subjects: 104
Study 36494045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi intervention, remotely delivered, twice a week for 12 weeks
Number of subjects: 0
Study 36494045 — intervention group
Group type: COMPARATOR
Intervention: Wellness control condition, remotely delivered, twice a week for 12 weeks
Number of subjects: 0
Study 33273302 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT at 630 nm (4.6 J·cm ‐2 , 97 J energy)
Number of subjects: 28
Study 33273302 — intervention group
Group type: EXPERIMENTAL
Intervention: LEDT at 940 nm (4.6 J·cm ‐2 , 114 J energy)
Number of subjects: 28
Study 33273302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 32139212 — intervention group
Group type: EXPERIMENTAL
Intervention: RHB-102 (24-mg bimodal-release ondansetron)
Number of subjects: 147
Study 32139212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 32276609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 30 cm H2O
Number of subjects: 134
Study 32276609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 40 cm H2O
Number of subjects: 134
Study 32276609 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak airway pressure at 50 cm H2O
Number of subjects: 134
Study 32276609 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 134
Study 36162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground coffee (1-5 cups/day)
Number of subjects: 449563
Study 36162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee (2-3 cups/day)
Number of subjects: 449563
Study 36162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (2-3 cups/day)
Number of subjects: 449563
Study 36162818 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground coffee (2-3 cups/day)
Number of subjects: 449563
Study 32215727 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) with olanzapine and metacognitive training (MCT) for 8 weeks
Number of subjects: 41
Study 32215727 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (DT) with olanzapine for 8 weeks
Number of subjects: 41
Study 32215727 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) with olanzapine and MCT
Number of subjects: 41
Study 32215727 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (DT) with olanzapine
Number of subjects: 41
Study 32928184 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety coping program (relaxation techniques, diaphragmatic breathing training, progressive muscle relaxation with light instrumental music)
Number of subjects: 76
Study 32928184 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study 32928184 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety coping program
Number of subjects: 76
Study 34304248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined DNA damage response (DDR) and BCL-2 inhibition
Number of subjects: 0
Study 34304248 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapies
Number of subjects: 0
Study 34034273 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG + 290 µg linaclotide (2 L PEG + L group)
Number of subjects: 432
Study 34034273 — intervention group
Group type: COMPARATOR
Intervention: 2 L PEG
Number of subjects: 432
Study 34034273 — intervention group
Group type: COMPARATOR
Intervention: 4 L PEG
Number of subjects: 432
Study 36366373 — intervention group
Group type: EXPERIMENTAL
Intervention: TURKOVAC
Number of subjects: 1290
Study 36366373 — intervention group
Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 1290
Study 32633242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrane (tropicamide 0.02%, phenylephrine 0.31%, lidocaine 1%)
Number of subjects: 64
Study 32633242 — intervention group
Group type: COMPARATOR
Intervention: Mydriatic drops (tropicamide 1% and phenylephrine 10%)
Number of subjects: 64
Study 32633242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydrane and mydriatic drops (both groups)
Number of subjects: 64
Study 35821033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + yoga (Study group, n = 121)
Number of subjects: 234
Study 35821033 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care (Control group, n = 113)
Number of subjects: 234
Study 35821033 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care + yoga (Study group)
Number of subjects: 234
Study 33232470 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized exercise training
Number of subjects: 116
Study 32915053 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger feeding method (Group 1, n=35)
Number of subjects: 70
Study 32915053 — intervention group
Group type: COMPARATOR
Intervention: Syringe feeding method (Group 2, n=35)
Number of subjects: 70
Study 35152908 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐PHP combined with ipilimumab and nivolumab
Number of subjects: 88
Study 34494129 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative breast reconstruction information (Group A)
Number of subjects: 100
Study 34494129 — intervention group
Group type: COMPARATOR
Intervention: No preoperative breast reconstruction information (Group B)
Number of subjects: 100
Study 35717284 — intervention group
Group type: EXPERIMENTAL
Intervention: Community navigator
Number of subjects: 40
Study 35717284 — intervention group
Group type: COMPARATOR
Intervention: Self-navigation of community resources
Number of subjects: 40
Study 35397159 — intervention group
Group type: EXPERIMENTAL
Intervention: IMT + WBV
Number of subjects: 42
Study 35397159 — intervention group
Group type: EXPERIMENTAL
Intervention: IMTsham + WBV
Number of subjects: 42
Study 35397159 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 42
Study 33980234 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) with metronidazole (MET) and oral hygiene instructions (OHI)
Number of subjects: 150
Study 33980234 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) + OHI
Number of subjects: 150
Study 33980234 — intervention group
Group type: COMPARATOR
Intervention: Oral hygiene instructions (OHI) only
Number of subjects: 150
Study 32195649 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim 80 mg
Number of subjects: 602
Study 32195649 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 15 mg/kg administered intravenously every 12 hours for 5-14 days
Number of subjects: 602
Study 32195649 — intervention group
Group type: EXPERIMENTAL
Intervention: Iclaprim
Number of subjects: 602
Study 32195649 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 602
Study 36165726 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus cetuximab
Number of subjects: 0
Study 36165726 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus cetuximab
Number of subjects: 0
Study 33369625 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Skill Training (MST)
Number of subjects: 154
Study 33369625 — intervention group
Group type: COMPARATOR
Intervention: Strength and Flexibility Exercise (SFE)
Number of subjects: 154
Study 35212648 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled lavender essence (diluted with sweet almond oil at a ratio of 1:10) administered before cannulation during 12 HD sessions.
Number of subjects: 24
Study 35212648 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra procedure performed).
Number of subjects: 24
Study 33610374 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD 60 µg
Number of subjects: 661
Study 33610374 — intervention group
Group type: COMPARATOR
Intervention: IIV4-SD (15 µg HA/strain)
Number of subjects: 661
Study 33610374 — intervention group
Group type: EXPERIMENTAL
Intervention: IIV4-HD
Number of subjects: 661
Study 32466588 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied to both masseter muscles, 6.0–7.5 mA, 20 min per day, five times a week for six weeks
Number of subjects: 40
Study 32466588 — intervention group
Group type: COMPARATOR
Intervention: Placebo NMES applied to both masseter muscles, 0.5 mA, 20 min per day, five times a week for six weeks
Number of subjects: 40
Study 34263919 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord clamping within 10 seconds (Group 1)
Number of subjects: 60
Study 34263919 — intervention group
Group type: COMPARATOR
Intervention: Cord clamping at 60 seconds (Group 2)
Number of subjects: 60
Study 34263919 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal and neonatal vitamin B12 levels correlation
Number of subjects: 60
Study 34396803 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing exercises with tape (n=19)
Number of subjects: 56
Study 34396803 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight bearing exercises without tape (n=18)
Number of subjects: 56
Study 34396803 — intervention group
Group type: COMPARATOR
Intervention: Control group not engaged in weight bearing exercises (n=19)
Number of subjects: 56
Study 32964468 — intervention group
Group type: EXPERIMENTAL
Intervention: Tell-us Card communication tool
Number of subjects: 265
Study 35343725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 227
Study 35343725 — intervention group
Group type: COMPARATOR
Intervention: Relaxation group therapy (RGT)
Number of subjects: 227
Study 35343725 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 227
Study 35343725 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (MBCT, RGT, TAU)
Number of subjects: 227
Study 32991788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARI) 10 mg
Number of subjects: 24
Study 32991788 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA) 5 mg
Number of subjects: 24
Study 32991788 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (ARI)
Number of subjects: 24
Study 32991788 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLA)
Number of subjects: 24